GSK-Pfizer deal illustrates risks and rewards of moving up the biopharma value chain
The potential rewards for drugmakers' investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.
GSK plans consumer health spinoff to strengthen focus on pharmaceuticals, vaccines
The British drugmaker plans to separate the consumer health joint venture with Pfizer announced Wednesday three years after the transaction closes.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
AstraZeneca looks to salvage data from negative Imfinzi lung cancer study
The company pointed to better survival numbers in patients with high tumor mutational burden, in a presentation at the ESMO immuno-oncology congress in Geneva.
May postpones vote on Brexit agreement that pharma sector had supported
The agreement would have allowed UK pharmaceutical regulations to remain under EMA authority after Brexit. Uncertainty around the planned withdrawal has caused worry in the life sciences sector.
Imfinzi looks flimsy in AstraZeneca’s Phase III head and neck cancer study
Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on platinum-based chemotherapy.
presented by
GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billion
In buying the US-based company for a 110 percent premium over its average 30-day share price, GSK hopes to beef up its oncology pipeline.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Report sounds alarm about Brexit risks to UK clinical trials environment
The Fitch Solutions report, released this week, notes that the number of clinical trials taking place in the UK has already fallen more than 25 percent.
Two months after closing a Series C round, Orchard Therapeutics files for $172.5M IPO
The London-based biotech would trade on the Nasdaq under the ticker symbol ORTX. The move comes two months after it closed a $150 million Series C and five months after it acquired a gene therapy portfolio from GSK.
VelosBio raises $58M in Series A round for antibody-drug conjugate development
Arix Bioscience co-leads round with Sofinnova Ventures, investing $11 million and taking an 11.2 percent ownership stake in the San Diego-based firm.
Genomics raises $32.5M to develop genetic database technology for drug development
Boston-based drugmaker Vertex Pharmaceuticals leads the round and also enters partnership with UK firm to aid its own drug development efforts.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
AI-based Healx raises $10 million for drug discovery
The UK company is the latest to join ranks of AI-focused drugmakers attracting venture capital.
GSK, 23andMe sign four-year drug-discovery partnership
Collaboration will leverage genetic testing company's data resources and pharma companies drug-development expertise.
How Cancer Research UK looked to the cloud for improved clinical trials efficiency
Reducing the burden of manual processes and paperwork by leveraging cloud technology meant that Cancer Research UK can now manage a larger portfolio of trials.
Emma Walmsley makes history as Big Pharma’s first female CEO
On Friday, GlaxoSmithKline's CEO of eight years, Andrew Witty, will formally retire and take a sliver of the proverbial glass ceiling with him. His replacement, Emma Walmsley, will be the first female head of a Big Pharma company.
BioBeats evolves from stress app to measurer of well-being
BioBeats makes apps that apply artificial intelligence in the cloud, looking for what CEO David Plans called "instances of well-being."